| Followers | 14 |
| Posts | 1735 |
| Boards Moderated | 0 |
| Alias Born | 01/21/2014 |
Friday, October 24, 2014 8:44:53 PM
then you should also be aware that they finished enrollment and all manufacturing in 2012
From IMUC's 10K
From January 2011 until September 2012, the trial enrolled 278 patients at 25 centers throughout the U.S. and 124 patients were randomized to ICT-107 or placebo
Does it really matter, the point is that their R&D expenses even in the heart of a Phase II trial were significantly less than ours.
2012 R&D -$7,711,233
2011 R&D -$4,988,612
Manufacturing became the key DOWNFALL for Dendreon. If you think it is such a good idea for NWBO to take the manufacturing in house, just look at what happened to Dendreon when they did that. That decision was a big factor in Dendreon's commercial failure.
Wow, and you call me misleading? DNDN's downfall had to do with manufacturing yes, but it had absolutely nothing to do with the fact that it was "in-house". It had everything to do with the fact that it was tedious for doctors to initiate, ship, manufacture, store, and the shelf life of the product, not to mention it cost a fortune.
NWBO's processes are second generation, NWBO's not Cognate's. NWBO has made these process advancements and from what I can gather, which isn't much seeing the company refuses to address the situation, is that Cognate is simply the entity in which produces NWBO's proprietary treatment with NWBO's proprietary processes. So as Dennis Hopper said to Christopher Walken in True Romance......am I lying?
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2025 09:23:24 PM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM
Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM
C2 Blockchain Reports 803 Million DOG (Bitcoin) Holdings Following Strategic Accumulation of Bitcoin-Native Digital Assets • CBLO • Mar 10, 2026 8:00 AM
RENI Completes Due Diligence on Target Acquisition; Confirms Strong Asset Base and Operational Performance • RENI • Mar 5, 2026 10:15 AM
BlackStar Engages in Talks with U.S. Senate Banking Committee Team Covering the Digital Asset Market Clarity Act • BEGI • Mar 4, 2026 4:47 PM
